0 BioPorto hopes to finish its clinical examination and present a De Novo application to the US FDA for pediatric utilization of its NGAL kidney test this late spring March 3, 2021 Editorial TeamThe Danish group likewise mentioned it anticipates US take a look at outcomes for its
